SCHEMBL4345309

SCHEMBL4345309

O=[N+]([O-])c1ccc(Oc2cc(Cl)ncn2)cc1.O=[N+]([O-])c1ccc(Oc2cc(Nc3ccccc3)ncn2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.47
ERBB2 P04626 1/20 0.47
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.47
LMNA P02545 3/20 0.47
MAPT P10636 3/20 0.47
KDR P35968 2/20 0.47
TNNI3K Q59H18 1/20 0.47
RAB9A P51151 3/20 0.46
HTT P42858 1/20 0.46
HPGD P15428 1/20 0.45
ALOX12 P18054 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NPC1 O15118 2/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TTBK1 Q5TCY1 1/20 0.43
TTBK2 Q6IQ55 1/20 0.43
SCN9A Q15858 1/20 0.42
FFAR1 O14842 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1894480 0.94 MEN1 (0.52) EGFRERBB2KMT2AMEN1LMNA
SCHEMBL4395583 0.89 NPC1 (0.55) EGFRERBB2KMT2AMEN1MAPT
SCHEMBL1891269 0.84 RAB9A (0.50) KMT2AMEN1LMNAMAPTRAB9A
SCHEMBL3166433 0.83 NPC1 (0.60) EGFRKMT2AMEN1MAPTRAB9A
SCHEMBL12664955 0.83 RAB9A (0.48) EGFRERBB2KMT2AMEN1LMNA
SCHEMBL3172396 0.83 ALK (0.50) EGFRERBB2KMT2AMEN1LMNA
SCHEMBL12262450 0.82 ALDH1A1 (0.53) EGFRERBB2KMT2AMEN1LMNA
SCHEMBL3166827 0.82 EGFR (0.49) EGFRERBB2KMT2AMEN1LMNA
SCHEMBL4929503 0.81 KMT2A (0.58) EGFRERBB2KMT2AMEN1MAPT
SCHEMBL12481913 0.80 NPC1 (0.56) EGFRKMT2AMEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612092-B2 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R & D MANAGEMENT CO., LTD. (JP) 2009-11-03 US disclosed
US-20060247259-A1 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247259-A1 Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective UGGT1, FLT1, GCG EGFR 586/4885ERBB2 1400/4885KMT2A 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.